Akeso: Advancing Immuno-Oncology with a Robust Pipeline and Innovative Assets
Akeso's Multi-Functional Platform and Pipeline
Akeso, a leading biopharmaceutical company, has established a fully integrated multi-functional platform that supports its robust pipeline of over 50 innovative assets in the fields of immuno-oncology and other therapeutic areas.
Investigator-Initiated Trials of Cadonilimab
Recently, Akeso published positive results from three investigator-initiated trials (IITs) evaluating its bispecific IO drug cadonilimab, a PD-1/CTLA-4 inhibitor. The results showed promising efficacy and safety profiles, further supporting the clinical development of cadonilimab in various cancer indications.
Clinical Stage Assets and Approved Drugs
Of the 50+ innovative assets in Akeso's pipeline, 19 have advanced to the clinical stage, including 13 ongoing Phase III studies. Additionally, three innovative drugs have already received regulatory approval, demonstrating Akeso's commitment to developing novel therapies for patients.
Kaixantini: A First-in-Class Immuno-Therapy Drug
Kaixantini, a novel first-in-class PD-1/CTLA-4 bi-specific immuno-therapy drug, is an in-house development by Akeso. This innovative asset has shown promising preclinical results and is currently being evaluated in clinical trials.
Upcoming Oral Presentations
Akeso recently announced two upcoming oral presentations at scientific conferences. These presentations will focus on the data from the investigator-initiated trials of ivonescimab, a PD-1/VEGF bispecific antibody, further highlighting Akeso's contributions to the field of immuno-oncology.
Komentar